This inventor holds 0 USPTO granted patents, plus 3 CIPO patents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Title: Kenji Masuda: Innovator in Protein Pharmaceuticals and Chronic Venous Insufficiency Treatments.
Introduction
Kenji Masuda is a notable inventor based in Japan, recognized for his contributions to the fields of protein pharmaceuticals and medical treatments. His innovative work has led to the development of significant patents aimed at enhancing the production of foreign proteins and addressing chronic venous insufficiencies.
Latest Patents
Masuda's latest patents include a method for enhancing the production of foreign proteins in host cells, specifically through the use of a transformed cell with a novel Hspa5 gene promoter. This invention aims to facilitate high-secretion production of foreign proteins, which are crucial for protein pharmaceuticals. Another significant patent focuses on a new composition for treating chronic venous insufficiencies, which combines an aqueous extract of red vine leaves with an anti-inflammatory agent. This composition is designed to alleviate discomfort associated with mild-to-moderate chronic venous insufficiency of the legs.
Career Highlights
Throughout his career, Kenji Masuda has worked with prominent companies such as Daiichi Sankyo Company, Limited and Boehringer Ingelheim International GmbH. His experience in these organizations has contributed to his expertise in the development of innovative medical solutions.
Collaborations
Masuda has collaborated with notable colleagues, including Koichi Nonaka and Hiroki Tanemura. These partnerships have played a significant role in advancing his research and inventions.
Conclusion
Kenji Masuda's work exemplifies the impact of innovation in the medical field, particularly in the areas of protein pharmaceuticals and treatments for chronic conditions. His contributions continue to influence advancements in healthcare and improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile